Good Start Genetics

Good Start Genetics, Inc. operated as a molecular diagnostics company with a focus on genetic testing services for inherited disorders, primarily within the reproductive health market. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company aimed to establish a new standard of care for genetic screening by providing clinically relevant information to physicians and prospective parents. The company's founder was Gregory Porreca. Don Hardison, an executive with experience at companies like LabCorp and Exact Sciences, was appointed President and CEO in 2010.

The company's business model revolved around providing advanced genetic testing services to a client base that included in vitro fertilization (IVF) clinics, obstetrician-gynecologist (Ob/Gyn) practices, and directly to consumers. Revenue was generated through the sale of these tests, which were often covered by insurance. The company pioneered the use of next-generation sequencing (NGS) in the reproductive health space, which allowed for a more simplified workflow and lower costs while maintaining high-quality results. Since its commercial launch in 2012, the company processed over 1.7 million tests.

Good Start Genetics developed a portfolio of products to address different stages of family planning. Its flagship in-clinic carrier screening service, GeneVu, offered a comprehensive menu of diagnostic tests for mutations causing inherited genetic disorders. For pre-implantation genetic screening, the company offered EmbryVu, which was based on technology licensed from Johns Hopkins University School of Medicine and designed for individuals using assisted reproduction. Recognizing the growing direct-to-consumer market, the company launched VeriYou, an at-home, physician-ordered carrier screening test that included genetic counseling and was available through Amazon. This multifaceted approach provided flexible and more affordable testing options for couples.

In a significant strategic move, Good Start Genetics was acquired by Invitae Corporation (NYSE: NVTA) in August 2017. The acquisition, valued at approximately $38.9 million, was part of Invitae's strategy to create a comprehensive genetic information platform covering all stages of life. The deal involved a combination of Invitae common stock and cash to retire Good Start's debt. Following the acquisition, Good Start Genetics became a wholly-owned subsidiary of Invitae, integrating its reproductive health testing services into Invitae's broader offerings. Keywords: genetic testing, molecular diagnostics, reproductive health, carrier screening, preimplantation genetic screening, next-generation sequencing, inherited disorders, IVF clinics, women's health, DNA sequencing, GeneVu, EmbryVu, VeriYou, genetic counseling, prenatal diagnosis, family planning, genetic information, inherited diseases, assisted reproduction, diagnostics services